(-)-JASMONIC ACID


UNII	900N171A0F
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	GEWDNTWNSAZUDX-WQMVXFAESA-N
Smiles	CC\C=C/C[C@@H]1[C@@H](CC(=O)OC)CCC1=O
InChI	InChI=1S/C13H20O3/c1-3-4-5-6-11-10(7-8-12(11)14)9-13(15)16-2/h4-5,10-11H,3,6-9H2,1-2H3/b5-4-/t10-,11-/m1/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C13H20O3
Molecular Weight	224.3
AlogP	2.36
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	6.0
Polar Surface Area	43.37
Molecular species	None
Aromatic Rings	0.0
Heavy Atoms	16.0

Assay Description	Organism	Bioactivity
Phytohormonal activity against Lepidium sativum assessed as inhibition of seed germination at 100 to 1000 uM after 2 days relative to control	Lepidium sativum	None
Phytohormonal activity against Oryza sativa (rice) seedlings assessed as growth inhibition of second leaf sheath at 1 to 300 uM after 5 days relative to control	Oryza sativa	None
Antifungal activity against Magnaporthe oryzae assessed as inhibition of appressorium formation at 100 ppm	Magnaporthe oryzae	150.0 ppm
Antifungal activity against Magnaporthe oryzae assessed as inhibition of spore germination	Magnaporthe oryzae	30.0 %
Antifungal activity against Magnaporthe oryzae assessed as inhibition of spore germination at 100 ppm	Magnaporthe oryzae	10.0 %
Antifungal activity against Magnaporthe oryzae assessed as inhibition of spore germination at 200 ppm	Magnaporthe oryzae	86.0 %
Antifungal activity against Magnaporthe oryzae assessed as inhibition of spore germination at 250 ppm	Magnaporthe oryzae	100.0 %

Cross References

Resources	Reference
ChEMBL	CHEMBL2139332
FDA SRS	900N171A0F
PubChem	5281929
SureChEMBL	SCHEMBL36186

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).